EA201200054A1 - Лечение токотриенолами или экстрактами, богатыми токотриенолами, первазивных расстройств развития - Google Patents

Лечение токотриенолами или экстрактами, богатыми токотриенолами, первазивных расстройств развития

Info

Publication number
EA201200054A1
EA201200054A1 EA201200054A EA201200054A EA201200054A1 EA 201200054 A1 EA201200054 A1 EA 201200054A1 EA 201200054 A EA201200054 A EA 201200054A EA 201200054 A EA201200054 A EA 201200054A EA 201200054 A1 EA201200054 A1 EA 201200054A1
Authority
EA
Eurasian Patent Office
Prior art keywords
tokotrienols
tocotrienol
rich
extracts
treatment
Prior art date
Application number
EA201200054A
Other languages
English (en)
Russian (ru)
Inventor
Гай М. Миллер
Original Assignee
Эмпэр Лайф Сайнсиз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эмпэр Лайф Сайнсиз, Инк. filed Critical Эмпэр Лайф Сайнсиз, Инк.
Publication of EA201200054A1 publication Critical patent/EA201200054A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
EA201200054A 2009-06-25 2010-02-25 Лечение токотриенолами или экстрактами, богатыми токотриенолами, первазивных расстройств развития EA201200054A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26962709P 2009-06-25 2009-06-25
PCT/US2010/025447 WO2010151348A1 (en) 2009-06-25 2010-02-25 Treatment of pervasive developmental disorders with tocotrienols or tocotrienol enriched extracts

Publications (1)

Publication Number Publication Date
EA201200054A1 true EA201200054A1 (ru) 2012-05-30

Family

ID=43386829

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201200054A EA201200054A1 (ru) 2009-06-25 2010-02-25 Лечение токотриенолами или экстрактами, богатыми токотриенолами, первазивных расстройств развития

Country Status (8)

Country Link
US (1) US20120122969A1 (cg-RX-API-DMAC7.html)
EP (2) EP2445519A4 (cg-RX-API-DMAC7.html)
JP (1) JP2012531411A (cg-RX-API-DMAC7.html)
BR (1) BRPI1011776A2 (cg-RX-API-DMAC7.html)
CA (1) CA2765771A1 (cg-RX-API-DMAC7.html)
EA (1) EA201200054A1 (cg-RX-API-DMAC7.html)
MX (1) MX2011013558A (cg-RX-API-DMAC7.html)
WO (1) WO2010151348A1 (cg-RX-API-DMAC7.html)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005033093A1 (en) 2003-09-19 2005-04-14 Galileo Pharmaceuticals, Inc. 7,8-bicycloalkyl-chroman derivatives
DK2471530T3 (en) * 2005-06-01 2017-04-10 Edison Pharmaceuticals Inc REDOXACTIVE THERAPEUTIC AGENTS FOR THE TREATMENT OF MITOCONDARY DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS
EP1986636B1 (en) 2006-02-22 2013-04-24 Edison Pharmaceuticals, Inc. Phenol and 1,4-benzoquinone derivatives for use in the treatment of mitochondrial diseases
HUE028502T2 (en) 2007-11-06 2016-12-28 Edison Pharmaceuticals Inc 4- (P-Quinonyl) -2-hydroxybutanamide derivatives for the treatment of mitochondrial diseases
EP2237664A4 (en) * 2008-01-08 2013-05-22 Edison Pharmaceuticals Inc (HET) ARYL-p-CHINONE DERIVATIVES FOR THE TREATMENT OF OCHONDRIAL DISEASES
US8716527B2 (en) 2008-03-05 2014-05-06 Edison Pharmaceuticals, Inc. 2-substituted-p-quinone derivatives for treatment of oxidative stress diseases
US8716486B2 (en) * 2008-06-25 2014-05-06 Edison Pharmaceuticals, Inc. 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases
LT3827815T (lt) 2008-09-10 2023-10-10 Ptc Therapeutics, Inc. Psichologinių raidos sutrikimų gydymas oksidacijos redukcijos atžvilgiu aktyviais vaistais
US10039722B2 (en) 2008-10-14 2018-08-07 Bioelectron Technology Corporation Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells
ES2553557T3 (es) 2008-10-28 2015-12-10 Edison Pharmaceuticals, Inc. Proceso para la producción de alfa-tocotrienol y derivados
HUE037574T2 (hu) 2009-04-28 2018-09-28 Bioelectron Tech Corp Leber-féle örökletes optikus neuropátia és domináns optikus atrofia kezelése tokotrienol kinonokkal
US20110207828A1 (en) * 2009-08-26 2011-08-25 Miller Guy M Methods for the prevention and treatment of cerebral ischemia
WO2013013078A1 (en) 2011-07-19 2013-01-24 Edison Pharmeceuticals, Inc. Methods for selective oxidation of alpha tocotrienol in the presence of non-alpha tocotrienols
JP6460998B2 (ja) * 2012-11-13 2019-01-30 インビクタス バイオテクノロジー プロプライエタリー リミテッド トコトリエノールの経粘膜送達
US9670170B2 (en) 2013-03-15 2017-06-06 Bioelectron Technology Corporation Resorufin derivatives for treatment of oxidative stress disorders
US9868711B2 (en) 2013-03-15 2018-01-16 Bioelectron Technology Corporation Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders
US9296712B2 (en) 2013-03-15 2016-03-29 Edison Pharmaceuticals, Inc. Resorufin derivatives for treatment of oxidative stress disorders
WO2015013285A2 (en) * 2013-07-22 2015-01-29 Ohio State Innovation Foundation Methods for reducing the occurrence of hot flashes
NZ733528A (en) 2014-12-16 2021-07-30 Ptc Therapeutics Inc Polymorphic and amorphous forms of (r)-2-hydroxy-2-methyl-4-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)butanamide
JP7117241B2 (ja) 2015-12-16 2022-08-12 ピーティーシー セラピューティクス， インコーポレイテッド 混合されたトコール組成物からアルファ－トコトリエノールを富化するための改良された方法
CA3008849A1 (en) 2015-12-17 2017-06-22 Bioelectron Technology Corporation Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders
JP2018083799A (ja) 2016-11-15 2018-05-31 バイオエレクトロン テクノロジー コーポレイション ２−置換アミノ−ナフト［１，２−ｄ］イミダゾール−５−オン化合物またはその製薬学上許容される塩
HUE066196T2 (hu) 2018-10-17 2024-07-28 Ptc Therapeutics Inc 2,3,5-trimetil-6-nonilciklohexa-2,5-dién-1,4-dion alfa-szinukleinopátiák, tauopátiák és egyéb rendellenességek szuppresszálására és kezelésére
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
US20220214358A1 (en) * 2019-04-05 2022-07-07 Arizona Board Of Regents On Behalf Of Arizona State University Diagnostic for childhood risk of autism spectrum disorder
MY196888A (en) * 2019-11-19 2023-05-08 Hovid Berhad A composition for managing cadasil
EP3981397A1 (en) * 2020-10-08 2022-04-13 Global Scientific Tocotrienols derivates, methods and uses thereof
CA3225266A1 (en) 2021-07-08 2023-01-12 Swathi PINNAMANENI Pharmaceutical compositions comprising 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0788376B2 (ja) 1986-09-02 1995-09-27 エーザイ株式会社 光学活性α−トコトリエノ−ルの製造方法
JP2685785B2 (ja) 1988-03-11 1997-12-03 エーザイ株式会社 光学活性α−トコトリエノールの製造方法
JPH029875A (ja) 1988-03-16 1990-01-12 Bio Ind Kyokai トコフェロール及びトコトリエノールの製造方法
US5157132A (en) 1990-05-18 1992-10-20 Carotech Associates Integrated process for recovery of carotenoids and tocotrienols from oil
EP0543417A1 (en) 1991-11-22 1993-05-26 Lipogenics, Incorporated Tocotrienols and tocotrienol-like compounds and methods for their use
US20030134028A1 (en) * 1995-06-01 2003-07-17 Lipton, Division Of Conopco, Inc. Fat based food products
JP2002501915A (ja) 1998-01-29 2002-01-22 イーストマン ケミカル カンパニー トコール含有混合物からのトコールの分離方法
US6472378B2 (en) 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
US6187811B1 (en) * 1998-10-28 2001-02-13 Lipogenics, Inc. Methods for treating benign prostatic hyperplasia using tocotrienols
WO2000027393A1 (en) 1998-11-06 2000-05-18 Fuji Chemical Industry Co., Ltd. Powders containing tocotrienols, process for producing the same and tablets prepared by compression molding the same
US6761903B2 (en) * 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US6395915B1 (en) 1999-09-10 2002-05-28 Technikrom, Inc. Method for producing purified tocotrienols and tocopherols using liquid chromatography
MY127451A (en) 1999-11-04 2006-12-29 Malaysian Palm Oil Board A method of chromatographic isolation for vitamin e isomers
US20030206972A1 (en) * 2000-10-13 2003-11-06 Babish John G. Compositions containing carotenoids and tocotrienols and having synergistic antioxidant effect
US20020155170A1 (en) * 2000-11-30 2002-10-24 Walsh William John Nutrient supplements and methods for treating autism and for preventing the onset of autism
US6838104B2 (en) 2000-12-20 2005-01-04 Archer Daniels Midland Company Process for the production of tocotrienols
US7217133B2 (en) * 2002-04-04 2007-05-15 Jeanine Thomas Method for treating pervasive development disorder
AT414082B (de) * 2002-05-03 2006-09-15 Vis Vitalis Lizenz & Handels Verfahren zur herstellung von tocotrienol-angereicherten präparationen
WO2005035491A2 (en) 2003-10-10 2005-04-21 Yasoo Health, Inc. PROCESS FOR SYNTHESIZING d-TOCOTRIENOLS FROM 2- VINYLCHROMANE COMPOUND
MXPA06009529A (es) 2004-02-23 2007-04-10 Texas A & M Univ Sys Composiciones antioxidantes y metodos para el uso de las mismas.
US10300034B2 (en) * 2007-02-22 2019-05-28 Children's Hospital Of Oakland Research Institute Fatty acid formulations and methods of use thereof
KR101481197B1 (ko) 2007-05-24 2015-01-09 로더스 크로클란 비.브이. 토코페롤 및 토코트리에놀을 함유하는 조성물의 제조방법

Also Published As

Publication number Publication date
CA2765771A1 (en) 2010-12-29
EP2445519A4 (en) 2012-12-26
MX2011013558A (es) 2012-04-30
WO2010151348A1 (en) 2010-12-29
EP2609921A1 (en) 2013-07-03
JP2012531411A (ja) 2012-12-10
EP2445519A1 (en) 2012-05-02
BRPI1011776A2 (pt) 2018-03-13
US20120122969A1 (en) 2012-05-17

Similar Documents

Publication Publication Date Title
EA201200054A1 (ru) Лечение токотриенолами или экстрактами, богатыми токотриенолами, первазивных расстройств развития
EA201692166A1 (ru) Гетероциклические ингибиторы глютаминазы
MX363223B (es) Tratamiento de trastornos generalizados del desarrollo con terapeuticos con actividad redox.
EA201492216A1 (ru) Ингибиторы бромодомена и их применение
BR112013013167A8 (pt) inibidores de bromodomínio e usos dos mesmos
EA201391290A1 (ru) Гетероциклические модуляторы синтеза липидов
EA201170396A1 (ru) 2-оксо-1,2-дигидрохинолиновые модуляторы иммунной функции
EA201291034A1 (ru) АПТАМЕРЫ К β-NGF И ИХ ПРИМЕНЕНИЕ ПРИ ЛЕЧЕНИИ B-NGF-ОПОСРЕДОВАННЫХ ЗАБОЛЕВАНИЙ И РАССТРОЙСТВ
EA201500362A1 (ru) Ингибиторы rho-киназы
CL2012003401A1 (es) Compuestos derivados de carbamato de hexafluoroisopropilo, inhibidores de la enzima monoacil glicerol lipasa (mgl); proceso de preparacion; medicamento; compuestos intermediarios; composicion farmaceutica; y su uso para tratar o prevenir dolores agudos o cronicos, vertigos, dislipidemias y epilepsia, entre otras enfermedades.
TR201816379T4 (tr) DNA-PK inhibitörleri.
EA201290919A1 (ru) Индазольные соединения и их применение
EA201270722A1 (ru) Формы рифаксимина и их применение
EA201291336A1 (ru) Замещенные 5-фтор-1н-пиразолопиридины и их применение
EA201790134A2 (ru) Соединения имидазопирролидинонов
EA201492005A1 (ru) Бензамидные производные для ингибирования активности abl1, abl2 и bcr-abl1
WO2014062720A3 (en) Methods of treating cancer
ECSP14015609A (es) Inhibidores de pde9 con estructura básica de imidazotriazinona
EA201591616A1 (ru) Трифторметил-замещенные аннелированные пиримидины и их применение
EA202190619A1 (ru) Противовирусные соединения
BR112015020389A2 (pt) compostos carbazol úteis como inibidores de bromodomínio
MX2009004798A (es) Tratamiento de los trastornos generalizados del desarrollo.
EA201171286A1 (ru) Новая технология изготовления индометацина
EA201790032A1 (ru) Бициклически замещённые урацилы и их применение
EA201590667A1 (ru) Ациламинопиримидиновые производные для лечения вирусных инфекций и других заболеваний